Regulator Proteins
Although the mechanisms of action of a number of Axon Ligands™ remain ambiguous, they can significantly affect biological processes of various kinds. While interacting with regulator proteins in this section, they may have therapeutic applications as their target proteins play a role in the regulation and/or facilitation of processes within the cell, without having enzymatic or transporting properties by themselves. Additionally, their mode of action may not have been elucidated in great detail, yet evidence has been found for a certain role in, for example: signaling pathways, apoptosis, or stem cell differentiation.
Calmodulin (CaM) is a ubiquitous regulatory protein that communicates the presence of calcium to its molecular targets and correspondingly modulates their function. This key signaling protein is important for controlling the activity of hundreds of membrane channels and transporters[1]. CaM contains two globular domains each containing a pair of helix-loop-helix Ca2+-binding sites (EF-hands). Upon Ca2+ binding, conformational transitions in calmodulin are induced that changes its affinity to target proteins[2]. One example of the proteins function being regulated by CaM is the family of auqaporins (AQPs): water channels that facilitate the flux of water molecules across membranes. Regulation of the water permeability by CaM is achieved through a Ca2+-dependent interaction between Ca2+-CaM and the cytoplasmic C-terminal domain of the AQP[3].
Avridine (Axon 2099), for example, is a lipoidal amine with interferon-inducing and adjuvant properties specifically related to Newcastle disease[4]. What’s more, although avridine is a synthetic non-immunogenic adjuvant, it is also known to induce arthritis in rats in a predictable and T-cell dependent way. However, the mechanism of action by which this Avridine Induced Arthritis (AvIA) is triggered, or acts as adjuvant of the Newcastle disease antigen has not been elucidated in detail[5].
[1] S.L. Reichow et al. Allosteric mechanism of water-channel gating by Ca2+-calmodulin. Nat. Struct. Mol. Biol. 2013, 20, 1085-1092.
[2] N.V. Valeyev et al. Elucidating the mechanisms of cooperative calcium-calmodulin interactions: a structural systems biology approach.BMC Systems Biol. 2008, 2, 48.
[3] S.L. Reichow et al. Allosteric mechanism of water-channel gating by Ca2+–calmodulin. Nat. Struct. Mol. Biol. 2013, 20, 1085-1092.
[4] M.M. Rweyemamu et al. Efficacy of avridine as an adjuvant forNewcastle disease virus antigen in chickens. Am. J. Vet. Res. 1986, 47, 1243-1248.
[5] C. Vingsbro, R. Jonsson, R. Holmdahl. Avridine-induced arthritis in rats; a T cell-dependent chronic disease influenced both byMHC genes and by non-MHC genes. Clin Exp Immunol 1995, 99, 359-363.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
3755 | (+)-Abscisic acid | LANCL2 ligand | €90.00 | |
1989 | (+)-JQ1 |
Potent and selective BET bromodomain inhibitor |
€60.00 | |
3822 | (+)-JQ1 carboxylic acid | (+)-JQ1 derivative; PROTAC precursor | €110.00 | |
3873 | (-)-JQ-1 | Inactive enantiomer of (+)-JQ1 | €120.00 | |
2830 | (R)-CE3F4 | Potent inhibitor of EPAC1 | €120.00 | |
3928 | (R)-SKBG-1 | Covalent RNA-binding protein NONO ligand | €160.00 | |
4192 | (S)-BI 2536 | Dual PLK1/BRD4 bromodomain inhibitor | €170.00 | |
3929 | (S)-SKBG-1 | Inactive enantiomer of (R)-SKBG-1 | €150.00 | |
3617 | 1R,3R-RSL3 (negative control) | Negative control of 1S,3R-RSL3 as GPX4 inhibitor | €90.00 | |
3957 | A-1155463 dihydrochloride | BH3 mimetic Ligand of BCL protein BCL-XL | Inquire | |
4008 | A-1210477 | Potent and selective inhibitor of MCL-1 | Inquire | |
3972 | A-1331852 | BH3 mimetic Ligand of BCL protein BCL-XL | €120.00 | |
3696 | ABBV-075 | Highly potent and orally bioavailable BET bromodomain (BRD) inhibitor | €110.00 | |
4263 | ABBV-467 | Potent and selective MCL-1 inhibitor | Recently added | Inquire |
3956 | ABBV-744 | First-in-class highly BDII (Bromodomain II)-selective BET bromodomain inhibitor | Inquire | |
3631 | ABR-238901 | Potent S100A8/A9 blocker | €170.00 | |
2141 | ABT 199 | Potent, orally bioavailable BCL-2-selective inhibitor | €70.00 | |
3821 | ABT-263 | Potent, selective and orally bioavailable inhibitor of B-cell lymphoma-2 (BCL-2) family proteins | Inquire | |
3687 | ADU-S100 | Cyclic dinucleotide (CDN) agonist (activator) of Stimulator of Interferon Genes (STING) | Inquire | |
3686 | AMG-176 | Potent and selective Mcl-1 inhibitor | €490.00 | |
3433 | ARB-272572 | Potent, cellular active PD-L1 inhibitor | €150.00 | |
3944 | ARV-825 | Potent and selective protein BRD4 degrader | Inquire | |
2099 | Avridine | Lipoidal amine; interferon-inducing and adjuvant properties | €80.00 | |
3814 | AZD4320 | BH3-mimetic inhibitor of BCL-2 protein | Inquire | |
3833 | AZD5153 HNT salt | Potent, selective, and orally available BET/BRD4 bromodomain inhibitor | Inquire | |
4139 | AZD5582 dihydrochloride | Apoptosis proteins (IAPs) inhibitor | Inquire | |
3731 | AZD5991 | BH3-Groove binding Mcl-1 inhibitor | Inquire | |
2185 | BAM 7 | Selective small-molecule activator of proapoptotic BAX | €90.00 | |
2774 | Barbadin | β-Arrestin/β2-Adaptin inhibitor | €120.00 | |
3714 | BCL-201 dihydrochloride | BH3-mimetic inhibitor of BCL-2 protein | Inquire |